Time to Detection of Growth for Mycobacterium tuberculosis in a Low Incidence Area
- PMID: 34490143
- PMCID: PMC8418320
- DOI: 10.3389/fcimb.2021.704169
Time to Detection of Growth for Mycobacterium tuberculosis in a Low Incidence Area
Abstract
Background: Diagnosis of Mycobacterium tuberculosis (MTB) infection can be confirmed by Xpert assays within hours. However, when sample size does not allow performing both culture and Xpert, or if Xpert is negative, then formal diagnosis of MTB relies on culture and time to detection of growth (TDG) becomes critical for clinical management.
Objectives: To determine TDG in Xpert negative samples, or in samples in which Xpert could not be performed, in a low-incidence area for MTB.
Methods: Retrospective analysis (2015-2020) of a database including all cultures for mycobacteria in a University Hospital covering approximately 500'000 inhabitants. Analysis was restricted to culture positive (C+) samples for MTB for which 1/Xpert was negative or could not be performed because of limited sample volume, and 2/collected from subjects treated less than 24 hours. TDG was analyzed according to microscopy, origin of sample (pulmonary or not) and presence of cavitation.
Results: Among 837 C+ samples for MTB, 236 samples (80% of respiratory origin) from 147 patients fulfilled study criteria; 78 samples (49 patients, 33%) were acid-fast bacilli (AFB) positive. Median (IQR) TDG was 25 (17; 40) days for all samples. TDG exceeded 28 days in 43% of samples and was significantly shorter in AFB+ vs AFB- samples, and samples from cavitary vs non cavitary or extra-thoracic disease.
Conclusions: In Xpert negative samples, or samples for which Xpert could not be performed, TDG exceeded 4 weeks in 43% of samples. AFB+ and samples from cavitary lung disease had a significantly shorter TDG.
Keywords: Mycobacterium tuberculosis; mycobacteria; mycobacterium growth indicator tube; nuclear acid amplification techniques; time to detection of growth.
Copyright © 2021 Vongthilath-Moeung, Poncet, Renzi, Schrenzel and Janssens.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.Clin Infect Dis. 2016 May 1;62(9):1081-8. doi: 10.1093/cid/ciw035. Epub 2016 Feb 2. Clin Infect Dis. 2016. PMID: 26839383 Free PMC article.
-
Performance Assessment of Xpert MTB/RIF Assay for Detecting Pulmonary Tuberculosis and Rifampin Resistance in a Tertiary Care Hospital in Korea.Jpn J Infect Dis. 2021 Nov 22;74(6):537-542. doi: 10.7883/yoken.JJID.2020.978. Epub 2021 Mar 31. Jpn J Infect Dis. 2021. PMID: 33790071
-
Use of a Single Xpert MTB/RIF Assay to Determine the Duration of Airborne Isolation in Hospitalized Patients With Suspected Pulmonary Tuberculosis.Infect Control Hosp Epidemiol. 2018 May;39(5):590-595. doi: 10.1017/ice.2018.25. Epub 2018 Mar 27. Infect Control Hosp Epidemiol. 2018. PMID: 29582718
-
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD013694. doi: 10.1002/14651858.CD013694.pub2. Cochrane Database Syst Rev. 2021. PMID: 33755189 Free PMC article.
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.Cochrane Database Syst Rev. 2019 Jun 7;6(6):CD009593. doi: 10.1002/14651858.CD009593.pub4. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Feb 22;2:CD009593. doi: 10.1002/14651858.CD009593.pub5. PMID: 31173647 Free PMC article. Updated.
Cited by
-
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.Ann Am Thorac Soc. 2023 Dec;20(12):1760-1768. doi: 10.1513/AnnalsATS.202302-144OC. Ann Am Thorac Soc. 2023. PMID: 38038600 Free PMC article.
-
Cell-free DNA blood test for the diagnosis of pediatric tuberculous meningitis.J Clin Tuberc Other Mycobact Dis. 2024 Feb 21;35:100421. doi: 10.1016/j.jctube.2024.100421. eCollection 2024 May. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 38420617 Free PMC article.
-
Making cough count in tuberculosis care.Commun Med (Lond). 2022 Jul 6;2:83. doi: 10.1038/s43856-022-00149-w. eCollection 2022. Commun Med (Lond). 2022. PMID: 35814294 Free PMC article. Review.
-
A case of novel, rapidly-growing Mycolicibacter kumamotonensis infection in a patient with severe pulmonary disease treated in New York City.BMC Infect Dis. 2023 Jan 13;23(1):26. doi: 10.1186/s12879-022-07959-2. BMC Infect Dis. 2023. PMID: 36639740 Free PMC article.
-
Tuberculosis in pregnancy.Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt A):34-44. doi: 10.1016/j.bpobgyn.2022.07.006. Epub 2022 Jul 31. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 36002371 Free PMC article. Review.
References
-
- Bisognin F., Lombardi G., Lombardo D., Re M. C., Dal Monte P. (2020). Comparison of MycoPrep and the New MYCO-TB Kit: Rapid and Efficient Digestion and Decontamination of Respiratory Specimens for the Detection of Mycobacteria. New Microbiol. 43 (1), 13–16. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources